Alprazolam extended-release in panic disorder

Bibliography

• EATON WW, KESSLER RC, WITTCHEN HU, MAGEE WJ: Panic and panic disorder in the United States. Am. J. Psychiatry(1994) 151:413–420.
   PubMed Web of Science ®Google Scholar
• WEISSMAN MM, BLAND RC, CANINO GJ et al.: The cross-national epidemiology of panic disorder. Arch. Gen. Psychiatry(1997) 54:305–309.
   PubMed Web of Science ®Google Scholar
• ROBINS LN, REGIER DA: Psychiatric disorders in America: the Epidemiologic Catchment Area Study. New York: Free Press, 1991.
   Google Scholar
• AMERICAN PSYCHIATRIC ASSOCIATION: Diagnostic and Statistical Manual of Mental Disorders (4th edit). American Psychiatric Press,Washington DC (1994).
   Google Scholar
• SPITZER RL, WILLIAMS JB, KROENKE K et al: Utility of a new procedure for diagnosing mental disorders in primary care: the PRIME MD 1000 Study. JAMA (1994) 272: 1749-1756.
   Google Scholar
• SHEAR MK, SCHULBERG HC: Anxiety disorders in primary care. Bull. Menninger Clin. (1995) 59(Suppl. 2A):A73–A85.
   Google Scholar
• TIEMENS BG, ORMEL J, SIMON GE: Occurrence, recognition, and outcome of psychological disorders in primary care. Am. J. Psychiatry(1996) 153:636–644.
   PubMed Web of Science ®Google Scholar
• MASSION AO, WARSHAW MG, KELLER MB: Quality of life and psychiatric morbidity in panic disorder and generalized anxiety disorder. Am. J. Psychiatry (1993) 150:600–607.
   PubMed Web of Science ®Google Scholar
• MARKOWITZ JS, WEISSMAN MM, OUELLETTE R et al.: Quality of life in panic disorder. Arch. Gen. Psychiatry (1989) 46:984–992.
   PubMed Web of Science ®Google Scholar
• KATON W, HOLLIFIELD M, CHAPMAN T et al.: Infrequent panic attacks: psychiatric comorbidity, personality characteristics and functional disability. Psychiatr. Res. (1995) 29:121–131.
   Google Scholar
• SHERBOURNE CD, WELLS KB, JUDD LL: Functioning and well-being of patients with panic disorder. Am. Psychiatry(1996) 153:213–218.
   PubMed Web of Science ®Google Scholar
• LEON AC, OLFSON M, PORTERA L: Service utilization and expenditures for the treatment of panic disorder. Gen. Hosp. Psychiatry (1997) 19:82–88.
   PubMed Web of Science ®Google Scholar
• WANG PS, BERGLUND P, KESSLER RC: Recent care of common mental disorders in the United States: prevalence and conformance with evidence- based recommendations. Gen. Intern. Med. (2000) 15:284–292.
   PubMed Web of Science ®Google Scholar
• REES CS, RICHARDS JC, SMITH LM: Medical utilisation and costs in panic disorder: a comparison with social phobia. Anxieh Disord. (1998) 12:421–435.
   PubMed Web of Science ®Google Scholar
• BREMNER JD, INNIS RB, WHITE T et al.: SPECT [I-1231 iomazenil measurement of the benzodiazepine receptor in panic disorder. Biol. Psychiatry (2000) 47:96–106.
   PubMed Web of Science ®Google Scholar
• MALIZIA AL, CUNNINGHAM VJ, BELL CJ, LIDDLE PF, JONES T, NUTT DJ: Decreased brain GABA(A)-benzodiazepine receptor binding in panic disorder: preliminary results from a quantitative PET study. Arch. Gen. Psychiatry (1998) 55:715–720.
   PubMed Web of Science ®Google Scholar
• KASCHKA W, FEISTEL H, EBERT D: Reduced benzodiazepine receptor binding in panic disorders measured by iomazenil SPECT.J Psychiatr. Res. (1995) 29:427–434.
   PubMed Web of Science ®Google Scholar
• KUIKKA JT, PITKANEN A, LEPOLA U et al.: Abnormal regional benzodiazepine receptor uptake in the prefrontal cortex in patients with panic disorder. Nucl. Med. Commun. (1995) 16:273–280.
   PubMed Web of Science ®Google Scholar
• SCHLEGEL S, STEINERT H, BOCKISCH A, HAHN K, SCHLOESSER R, BENKERT 0: Decreased benzodiazepine receptor binding in panic disorder measured by IOMAZENIL-SPECT. Ear: Arch. Psychiatry Clin. Neurosci. (1994) 244:49–51.
   Google Scholar
• GODDARD AW, MASON GE ALMAI A et al.: Reductions in occipital cortex GABA levels in panic disorder detected with 1H-magnetic resonance spectroscopy. Arch. Gen. Psychiatry (2001) 58:556–561.
   Google Scholar
• ROY-BYRNE PP, COWLEY DS, GREENBLATT DJ, SHADER RI, HOMMER D: Reduced benzodiazepine sensitivity in panic disorder. Arch. Gen. Psychiatry (1990) 47:534–538.
   PubMed Web of Science ®Google Scholar
• ROY-BYRNE P, WINGERSON DK, RADANT A, GREENBLATT DJ, COWLEY DS: Reduced benzodiazepine sensitivity in patients with panic disorder: comparison with patients with obsessive-compulsive disorder and normal subjects. Am. J. Psychiatry(1996) 153:1444–1449.
   PubMed Web of Science ®Google Scholar
• CHARNEY DS: Neuroanatomical circuits modulating fear and anxiety behaviors. Acta Psychiatr. Scand. (2003) (Suppl.):38–50.
   Google Scholar
• CALDJI C, DIORIO J, MEANEY MJ: Variations in maternal care in infancy regulate the development of stress reactivity. Biol. Psychiatry (2000) 48:1164–1174.
   PubMed Web of Science ®Google Scholar
• GORMAN JM, KENT JM, SULLIVAN GM, COPLAN JD: Neuroanatomical hypothesis of panic disorder, revised. Am. J. Psychiatry (2000) 157:493–505.
   PubMed Web of Science ®Google Scholar
• KENT JM, MATHEW SJ, GORMAN JM:Molecular targets in the treatment of anxiety. Biol. Psychiatry (2002) 52:1008–1030.
   PubMed Web of Science ®Google Scholar
• KAPLAN GB, GREENBLATT DJ, EHRENBERG BL, GODDARD JE, HARMATZ JS, SHADER RI: Differences in pharmacodynamics but not pharmacokinetics between subjects with panic disorder and healthy subjects after treatment with a single dose of alprazolam. Clin. Psychopharmacol (2000) 20:338–346.
   PubMed Web of Science ®Google Scholar
• SCHWEIZER E, RICKELS K, WEISS S, ZAVODNICK S: Maintenance drug treatment of panic disorder. I. Results of a prospective, placebo-controlled comparison of alprazolam and imipramine. Arch. Gen. Psychiatry (1993) 50:51–60.
   Google Scholar
• RICKELS K, SCHWEIZER E: Panic disorder: long-term pharmacotherapy and discontinuation. J. Clin. Psychopharmacol (1998) 18(6 Suppl. 2):125–185.
   Google Scholar
• LOW K, CRESTANI F, KEIST R et al: Molecular and neuronal substrate for the selective attenuation of anxiety. Science (2000) 290:131–134.
   PubMed Web of Science ®Google Scholar
• WINGROVE PB, SAFO P, WHEAT L, THOMPSON SA, WAFFORD KA, WHITING PJ: Mechanism of alpha-subunit selectivity of benzodiazepine pharmacology at gamma-aminobutyric acid type A receptors. Ear: Pharmacol (2002) 437:31–39.
   PubMed Web of Science ®Google Scholar
• KRALIC JE, KORPI ER, O'BUCKLEY TK, HOMANICS GE, MORROW AL: Molecular and pharmacological characterization of GABA(A) receptor alpha], subunit knockout mice. I Pharmacol Exp. Ther. (2002) 302:1037–1045.
   PubMed Web of Science ®Google Scholar
• KRALIC JE, O'BUCKLEY TK, KHISTI RT, HODGE CW, HOMANICS GE, MORROW AL: GABA(A) receptor alpha-1 subunit deletion alters receptor subtype assembly, pharmacological and behavioral responses to benzodiazepines and zolpidem. Neuropharmacology (2002) 43:685–694.
   PubMed Web of Science ®Google Scholar
• RICKELS K, DOWNING R, SCHWEIZER E, HASSMAN H: Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch. Gen. Psychiatry (1993) 50:884–895.
   PubMed Web of Science ®Google Scholar
• HOEHN-SARIC R, MCLEOD DR, ZIMMERLI WD: Differential effects of alprazolam and imipramine in generalized anxiety disorder: somatic versus psychic symptoms.' Clin. Psychiatry (1988) 49:293–301.
   PubMed Web of Science ®Google Scholar
• SCHWEIZER E, RICKELS K, WEISS S,ZAVODNICK S: Maintenance drug treatment of panic disorder. I. Results of a prospective, placebo-controlled comparison of alprazolam and imipramine. Arch. Gen. Psychiatry (1993) 50:51–60.
   Google Scholar
• ROY-BYRNE PP, STANG P, WITTCHEN HU, USTUN B, WALTERS EE, KESSLER RC: Lifetime panic-depression comorbidity in the National Comorbidity Survey. Association with symptoms, impairment, course and help-seeking. Br. J. Psychiatry (2000) 176:229–235.
   Google Scholar
• KELLER MB, LAVORI PW, GOLDENBERG IM et al.: Influence of depression on the treatment of panic disorder with imipramine, alprazolam and placebo.' Affect. Disoid. (1993) 28:27–38.
   PubMed Web of Science ®Google Scholar
• RICKELS K, CHUNG HR, CSANALOSI IB et al.: Alprazolam, diazepam, imipramine, and placebo in outpatients with major depression. Arch. Gen. Psychiatry (1987) 44:862–866.
   PubMed Web of Science ®Google Scholar
• AMERICAN PSYCHIATRIC ASSOCIATION: Panic disorder treatment guideline. Am. I Psychiatry (1998) 155(5 Suppl.):1–34.
   Google Scholar
• WOODS JH, KATZ JL, WINGER G: Abuse liability of benzodiazepines. Pharmacol Rev (1987) 39:251-413; Erratum in: Pharmacol Rev (1988) 40(1):85.
   Google Scholar
• WOODS JH, KATZ JL, WINGER G: Benzodiazepines: use, abuse and consequences. Pharmacol Rev (1992) 44:151–347.
   PubMed Web of Science ®Google Scholar
• DE WIT H, UHLENHUTH DH, EDEKER D, MCCRACKEN SG, JOHANSON CE: Lack of preference for diazepam in anxious volunteers. Arch. Gen. Psychiatry (1986) 43:553–561.
   PubMed Web of Science ®Google Scholar
• ROMACH M, BUSTO U, SOMER G, KAPLAN HL, SELLERS E: Clinical aspects of chronic use of alprazolam and lorazepam. Am. J. Psychiatry (1995) 152:1161–1167.
   PubMed Web of Science ®Google Scholar
• WRIGHT CE: Clinical pharmacokineticsof alprazolam extended release: a summary. Carr. Ther. Res. (1995) 56:947–956.
   Web of Science ®Google Scholar
• WRIGHT CE, SISSON TL, FLEISHAKERJC, ANTAL EJ: Pharmacokinetics and psychomotor performance of alprazolam: concentration-effect relationship. J. Clin. Pharmacol (1997) 37:321–329.
   PubMed Web of Science ®Google Scholar
• HOSSAIN M, WRIGHT E, BAWEJA R, LUDDEN T, MILLER R: Nonlinear mixed effects modeling of single dose and multiple dose data for an immediate release (IR) and a controlled release (CR) dosage form of alprazolam. Pharm. Res. (1997) 14:309–315.
   PubMed Web of Science ®Google Scholar
• GREENBLATT DJ, VON MOLTKE LL, HARMATZ JS, CIRAULO DA, SHADER RI: Alprazolam pharmacokinetics, metabolism, and plasma levels: clinical implications." Clin. Psychiatry (1993) 54(Suppl.):4–11.
   Google Scholar
• HARNETT-SHEEHAN K, SHEEHAN DV, RAJ BA: Speed of onset of clinical benefit of alprazolam-XR versus alprazolam-CT in panic disorder. Poster presentation at the 4th International Forum on Mood and Anxiety Disorders, Monte-Carlo, Monaco. November 19-21(2003).
   Google Scholar
• PRESCRIPTION RATES FOR ANXIOLYTICS: IMS MAT/Q3/1998 - MAT/Q3/2003, N5C Tranquilizers Prescribed for Panic Disorder (F410), Tranquilizer Dataview Database, IMS Health, Plymouth Meeting, PA, USA.
   Google Scholar
• BANDELOW B: Assessing the efficacy oftreatments for panic disorder and agoraphobia. II. The Panic and Agoraphobia Scale. Int. Clin. Psychopharmacol (1995) 10:73–81.
   PubMed Web of Science ®Google Scholar
• SHEAR MK, BROWN TA, BARLOW DH et al.: Multicenter collaborative panic disorder severity scale. Am. J. Psychiatry (1997) 154:1571–1575.
   PubMed Web of Science ®Google Scholar
• SCHWEIZER E, PATTERSON W, RICKELS K, ROSENTHAL M: Double-blind, placebo-controlled study of a once-a-day, sustained-release preparation of alprazolam for the treatment of panic disorder. Am. J. Psychiatry (1993) 150:1210–1215.
   PubMed Web of Science ®Google Scholar
• PECKNOLD J, LUTHE L, MUNJACK D,ALEXANDER P: A double-blind, placebo-controlled, multicenter study with alprazolam and extended-release alprazolam in the treatment of panic disorder. Psychopharmacol (1994) 14:314–321.
   Web of Science ®Google Scholar
• SHEEHAN DV, RAJ AB, HARNETT-SHEEHAN K et al.: Method for assessing the duration of therapeutic action and milligram equivalence of amdolytics. Anxiety (1996) 2:40–46.
   PubMedGoogle Scholar
• Pharmacia Corp.: Alprazolam-XR, US Product Information.
   Google Scholar
• Pharmacia Corp.: Alprazolam, US Product Information.
   Google Scholar
• GLADSJO JA, RAPAPORT MH, MCKINNEY R et al.: Absence of neuropsychologic deficits in patients receiving long-term treatment with alprazolam-XR for panic disorder. Psychopharmacol (2001) 21:131–138.
   Web of Science ®Google Scholar
• MUMFORD GK, EVANS SM, FLEISHAKER JC, GRIFFITHS RR: Alprazolam absorption kinetics affects abuse liability. Clin. Pharmacol The]: (1995) 57:356–365.
   PubMed Web of Science ®Google Scholar
• BUSTO UE, RUIZ I, BUSTO MA et al:Benzodiazepine use in Chile: impact of availability on abuse and dependence. Psychopharmacol (1996) 16:363–372.
   Web of Science ®Google Scholar
• ROMACH MK, BUSTO U, SOBELL LC et al.: Long-term alprazolam use: abuse, dependence or treatment. Psychopharm. Bull. (1991) 27:391–395.
   PubMedGoogle Scholar
• SCHWEIZER E, RICKELS K: Benzodiazepine dependence and withdrawal: a review of the syndrome and its clinical management. Acta Psychiam Scand. Sapp]. (1998) 393:95–101.
   PubMedGoogle Scholar
• POLLACK MH, ALLGULANDER C, BANDELOW B et al., World Council of Anxiety: WCA recommendations for the long-term treatment of panic disorder. CNS Sperm. (2003) 8(8 Suppl. 1):17–30.
   Google Scholar